Author's reply: Letter to the editor in response to Akita et al. (2020)

Affiliations

¹ Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
² Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
³ Department of Cardiology, Aichi Medical University, Aichi 480-1195, Japan.
⁴ Department of Cardiology, Tokai University, Kanagawa 259-1193, Japan.

Comment

Keitaro Akita et al. Eur Heart J Cardiovasc Pharmacother. 2021.

. 2021 May 23;7(3):e60.

doi: 10.1093/ehjcvp/pvaa113.

¹ Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
² Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
³ Department of Cardiology, Aichi Medical University, Aichi 480-1195, Japan.
⁴ Department of Cardiology, Tokai University, Kanagawa 259-1193, Japan.

No abstract available

Comment on

Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Akita K, Inohara T, Yamaji K, Kohsaka S, Numasawa Y, Ishii H, Amano T, Kadota K, Nakamura M, Maekawa Y. Akita K, et al. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):231-238. doi: 10.1093/ehjcvp/pvz056. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31593213
Letter to the editor in response to Akita et al. 2020.
Seligmann G, Ponnampalam J, Pimento D, Little C. Seligmann G, et al. Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e52. doi: 10.1093/ehjcvp/pvaa112. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32991695 No abstract available.